BRAND_ANALYSIS #NOVO_NORDISK HEALTH & PHARMA #1 OF 26 IN HEALTH & PHARMA HIGH TENSION

Novo Nordisk

· Public · Updated 25 May 2026 11:16 UTC
#8 of 1208 overall by tension · #1 of 26 in Health & Pharma
40 High Tension
The Silent Giant
Analysis

Novo Nordisk's culture and business scores mirror Google's exactly — 57 and 97 — but the story is entirely different: this is a pharma company that became a cultural object by manufacturing scarcity around a weight-loss drug. Sentiment at 0.60 is impressively warm for healthcare. The 16.72% stock gain is almost beside the point when the brand is being debated in dinner conversations worldwide.

IN THE NEWS (100 articles this week)
EMA backs Novo's Wegovy pill, first oral weight-loss drug for Europe - Reuters
Novo Nordisk accelerates clinical insight with custom agents on Azure - Microsoft
European Regulator Backs Novo Nordisk’s Wegovy Weight-Loss Pill - WSJ
Cultural Score
57 / 100
Business Score
97 / 100
TENSION▂▂▂▂▂▃▃▃▃▃▃▃▃▃
CULTURAL▄▄▄▄▄▄▄▄▄▄▄▄▄▄
BUSINESS▆▆▆▆▆▇▇▇▇▇▇▇▇▇
Loading...
Wikipedia Momentum 15/40
News Presence 43/35
Search InterestRedistributed to other dimensions
Stock Momentum 30/30
Market Position 22/25
Revenue Growth 25/25
Earnings Health 20/20
Price$44.96
30d Change+16.7%
Market Cap$199.3B
Profit Margin37.2%
Novo Nordisk's tension is 40. Commerce outpacing culture. sociologyofcapitalism.com/brand/novo-nordisk
SHARE ON X
EMBED
<iframe src="https://sociologyofcapitalism.com/embed/novo-nordisk.html" width="320" height="200" frameborder="0"></iframe>